42 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27597413	58	Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.	Southern Medical University
27606546	218	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.	University Of Navarra
27301679	21	Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.	Takeda Pharmaceutical
26978121	20	Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.	Sun Yat-Sen University
26789933	100	Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.	Intra-Cellular Therapies
26935942	41	Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.	Mercachem
26562545	13	Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.	Institute Of Radiopharmaceutical Cancer Research
26526739	35	Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.	Southern Medical University
25815146	29	Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.	Janssen Pharmaceutica
25801159	36	Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.	Csir-Indian Institute Of Integrative Medicine
25495612	10	(±)-Torreyunlignans A-D, rare 8-9' linked neolignan enantiomers as phosphodiesterase-9A inhibitors from Torreya yunnanensis.	Sun Yat-Sen University
25456383	113	Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.	TBA
25432025	34	Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.	Sun Yat-Sen University
25221665	33	Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.	Janssen Pharmaceutica
23260348	91	Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.	Janssen-Cilag
23137303	38	Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.	Chinese Academy Of Sciences
23025719	32	Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.	Pfizer
22985069	18	Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.	Sun Yat-Sen University
22780914	35	Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.	Pfizer
22483586	10	Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.	Sun Yat-Sen University
15887951	29	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.	Monash University (Parkville Campus)
22142545	96	Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.	Merck Research Laboratories
21988093	316	Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.	Pfizer
21983442	142	Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.	Biocrea
20450197	80	Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.	Biotie Therapies
20121115	3	Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.	University Of North Carolina
19631533	126	Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.	Pfizer
19919087	55	Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.	Pfizer
19049349	107	Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.	Georgia State University
16275071	26	A new chemical tool for exploring the physiological function of the PDE2 isozyme.	Pfizer
16263279	37	A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.	Pfizer
15837326	51	Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.	Schering-Plough Research Institute